Photo by usgs from unsplash
Abstract Context: Several assays of monitoring immune cell function have been developed to enhance therapeutic drug monitoring. Objective: An in vitro-validated whole-blood assay of phosphorylated ribosomal protein S6 (pS6RP) was… Click to show full abstract
Abstract Context: Several assays of monitoring immune cell function have been developed to enhance therapeutic drug monitoring. Objective: An in vitro-validated whole-blood assay of phosphorylated ribosomal protein S6 (pS6RP) was evaluated for confounders to monitor the mTOR-inhibitor everolimus (ERL). Materials and methods: Whole blood samples from 87 heart transplant recipients were analyzed for pS6RP-expression in CD3-positive T-cells by phospho-flow analysis. Results: ERL blood concentration, laboratory parameters, co-medications, demographic and clinical data were reviewed. Conclusion: Evaluating the pS6RP-assay revealed that pS6RP is influenced by cyclosporine A (CsA) blood concentration, duration of ERL treatment, co-medication with thiazide diuretics and different metabolic parameters.
Journal Title: Biomarkers
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!